Capitalizing on space’s microgravity, the United Therapeutics–partnered Varda Space Industries aims to make medicines with ...
Results from the Phase 3 part of AMETHYST are expected in the first half of 2027; in January 2026 the FDA granted ...
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced new data evaluating the efficacy and safety of POMBILITI ® ...
In 2025, the AAP updated its guidance to recommend exome or genome sequencing as a first-tier test for children with global ...
Includes worldwide license to ABO2203, Abogen's mRNA-encoded CD19xCD3 T-Cell Engager . Agreement also gives Novartis ...
CaseBioscience® today announced its participation in a multidisciplinary team led by Likarda that has been awarded up to $7.3 ...
Kailera Therapeutics and Hengrui Pharma’s weekly injection showed benefits beyond weight loss in a mid-stage trial, leading ...
Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, plans to release its ...
(“Axogen” or the “Company”) (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the ...
Bristol Myers Squibb will soon release Phase 3 data for admilparant that could make or break Contineum Therapeutics’ rival ...
Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting ...
Despite meeting the primary endpoints in a Phase 3 trial, shares of Zealand Pharma dropped in premarket trading Thursday as ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results